Skip to main content
. 2023 Feb 22;14:993. doi: 10.1038/s41467-023-36637-3

Fig. 2. Comparing ASGARD to bulk-cell-based repurposing methods.

Fig. 2

The receiver operating characteristic (ROC) curves and area under curve (AUC) scores of the ASGARD, on advanced metastatic breast cancer, acute lymphoblastic leukemia, and coronavirus disease 2019 (COVID-19), respectively. a Comparison among different DE analysis methods Limma (red), DESeq2 (light blue), Seurat (green), and edgeR (blue) using the best-performing mode in each. b Comparison of ASGARD (red) and bulk-sample based drug repurposing methods: CLUE (blue), and DrInsight (green), using the same three diseases as in a. The single-cell RNA-Seq data were aggregated to pseudo-bulk RNA-Seq data as the input of the bulk-sample based methods. Source data are provided as a Source Data file.